MYCN amplification occurs in ~20% of neuroblastomas and has been established as a key driver of an aggressive and chemoresistant tumour phenotype, frequently observed in high-risk neuroblastoma and predictive of poor patient outcome [20,25]. This evidence concerns the gene MYCN and neoplasm.